MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 6, 2008; DOI: 10.1124/mol.108.049825


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.049825v1
74/5/1171    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Mackie, A. R
Right arrow Articles by Byron, K. L
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mackie, A. R
Right arrow Articles by Byron, K. L


Received for publication June 19, 2008.
Revised August 5, 2008.
Accepted for publication August 5, 2008.

Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention

Alexander R Mackie 1 Kenneth L Byron 1*

1 Loyola University Chicago

* Address correspondence to: E-mail: kbyron{at}lumc.edu

Abstract

Potassium channels play an important role in electrical signaling of excitable cells such as neurons, cardiac myocytes, and vascular smooth muscle cells (VSMCs). In particular, the KCNQ (Kv7) family of voltage-activated K+ channels functions to stabilize negative resting membrane potentials and thereby opposes electrical excitability. Of the five known members of the mammalian Kv7 family, Kv7.1 was originally recognized for its role in cardiac myocytes where it contributes to repolarization of the cardiac action potential. Kv7.2-7.5 were first discovered in neurons where they play a well characterized role in neurotransmitter-stimulated action potential firing. Over the past five years, important new roles for Kv7 channels have been identified. Kv7 channels have been found to be expressed in VSMCs from several vascular beds where they contribute to the regulation of vascular tone. There is evidence that Kv7.5 channels in VSMCs are targeted by the hormone vasopressin to mediate its physiological vasoconstrictor actions and neuronal Kv7 channels in the baroreceptors of the aortic arch adjust the sensitivity of the mechanosensitive neurons to changes in arterial blood pressure. These newly identified physiological roles for Kv7 channels in the cardiovascular system warrant increased attention because pharmacological modulators of this family of channels are being used clinically to treat a variety of neurological disorders. This raises questions about the cardiovascular side effects associated with existing therapies, but there is also obvious potential to capitalize on the established and evolving pharmacology of these channels to develop new therapies for cardiovascular diseases.


Key words: Vasopressin/Oxytocin, Ion channel regulation, Potassium, Gq/11 family, Calcium (G Protein Coupled Signals)





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics